Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815730 | 0.82 | VEGFA (0.34) | GPR6MEN1KMT2ANPC1TP53 | |
| SCHEMBL17815736 | 0.81 | SCN9A (0.33) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL23207662 | 0.80 | GPR6 (0.38) | GPR6NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL17815701 | 0.77 | PDE4B (0.38) | GPR6NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL10304986 | 0.70 | RAB9A (0.45) | KMT2ANPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL24042971 | 0.69 | PDE4A (0.34) | GPR6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24042861 | 0.69 | PDE4B (0.46) | GPR6MEN1KMT2A | |
| SCHEMBL17815743 | 0.69 | IDH1 (0.36) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL13019367 | 0.68 | SMN1; SMN2 (0.36) | MEN1KMT2ANPC1TP53RAB9A | |
| SCHEMBL17815702 | 0.68 | MEN1 (0.32) | MEN1KMT2ANPC1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | GPR6 690/4885MEN1 4450/4885KMT2A 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.